Clinical Trial Update: First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Completion of a Phase 2 trial evaluating first-line FOLFOXIRI in combination with bevacizumab for metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Colorectal Cancer Metastatic | Phase 2 | Status: COMPLETED